<DOC>
	<DOCNO>NCT02121847</DOCNO>
	<brief_summary>This study evaluate safety efficacy cyclosporine 0.05 % ophthalmic emulsion ( RestasisÂ® ) patient dry eye disease .</brief_summary>
	<brief_title>Investigation Maintaining Visual Performance Achieved With Cyclosporine Therapy</brief_title>
	<detailed_description />
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<mesh_term>Lubricant Eye Drops</mesh_term>
	<mesh_term>Carboxymethylcellulose Sodium</mesh_term>
	<criteria>History dry eye eye Willing use eye drop dry eye symptom Anticipate wear contact lens study Laserassisted situ keratomileusis ( LASIK ) surgery within past 12 month Any ocular and/or lid surgery within past 6 month Cataract surgery either eye Current anticipate use temporary punctal plug study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>